| Name | Title | Contact Details |
|---|
Calithera is discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Tumor metabolism and tumor immunology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients. Our lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. We are currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors. In tumor immunology, our lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Our ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.
Antibe Therapeutics develops safer medications for chronic pain and inflammation. Today, physicians and consumers rely principally on non-steroidal anti-inflammatory drugs (NSAIDs), a $12 billion category of medications that includes brands like Advil, Aleve, Motrin, Celebrex, Voltaren and Aspirin. While effective, NSAIDs can cause gastrointestinal damage and bleeding. To address this serious medical need, Antibe has patented a technology for linking NSAID molecules to hydrogen sulfide molecules. More than a decade of academic and applied research has demonstrated that hydrogen sulfide, when appropriately delivered, can protect the gastrointestinal tract and enhance the anti-inflammatory effectiveness of today’s NSAIDs. Beginning with its IPO in mid-2013, Antibe has raised more than $10 million and initiated human clinical trials of its first drug, aimed at mild to moderate pain.
Tris Pharma, Inc. is one of the top five privately-owned specialty pharmaceutical companies in the U.S. with a focus on the development of pharmaceutical science and technology-based products. Specifically, we are engaged in research, development, manufacturing, and commercialization of both branded products and specialty generic products. We have more than a dozen solid and liquid products in the U.S. market based on our numerous NDAs and ANDAs and a rich and growing portfolio of more than 30 U.S. granted patents. Our commercialization success is driven by internal resources for our pediatric products and by licensing of our non-pediatric products to other companies. Our mission is to understand the science of developing drug products with unique attributes, bring to market products that add value to our patients and customers, and provide a benefit to our company, employees and society at large.
Ambit Biosciences is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte`s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and the XpressCFᵀᴹ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company`s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte`s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.